Target intelligence / Profile preview

Adaptor protein complex AP-3 subunit beta-1 (AP3B1)

Target
AP3B1
Molecular classification
Other (Adaptor protein complex subunit; Vesicular trafficking protein)
01

Overview

Adaptor protein complex AP-3 subunit beta-1 (AP3B1) is the β3A subunit of the heterotetrameric AP-3 protein complex, which mediates vesicle formation and protein sorting primarily from the trans-Golgi network and endosomes to lysosome-related organelles such as melanosomes, lysosomes, and platelet dense granules[1][2][3][5]. AP3B1 is essential for the proper biogenesis of these organelles and participates in trafficking pathways that are critical for pigmentation, hemostasis, and immune cell function. Loss-of-function mutations cause Hermansky–Pudlak syndrome type 2 (HPS2), a disorder featuring oculocutaneous albinism, platelet storage pool deficiency (bleeding tendency), susceptibility to infections (immunodeficiency), and increased risk of pulmonary fibrosis[1][2][3][4]. AP3B1 interacts with clathrin and helps to recognize cargo proteins destined for transport, notably playing a partially redundant role with AP-1 in trafficking proteins (such as tyrosinase) to melanosomes[5]. While not a classic therapeutic target such as a receptor or enzyme, AP3B1 is of major interest in rare genetic disease, organelle biology, and protein trafficking research contexts.

Other names
AP-3 complex subunit beta-1ADTB3ADTB3AHPSHPS2PEadaptor related protein complex 3 beta 1 subunitadaptor related protein complex 3 subunit beta 1beta-3Abeta-3A-adaptinclathrin assembly protein complex 3 beta-1 large chain
02

Biological functions

Organelle biogenesis (melanosomes, platelet dense granules, lysosomes)Vesicle-mediated protein sorting and traffickingEndosomal transportImmune response modulation (e.g., cytotoxic T cell and NK cell function)Regulation of macroautophagyRegulation of membrane protein localization
03

Disease associations

Hermansky-Pudlak syndrome type 2 (HPS2)Bleeding diathesis/platelet function disordersCutaneous albinism/pigmentation defectsImmunodeficiencyPulmonary fibrosisPotential cancer/inflammatory disease contributing factor
04

Safety considerations

Not directly relevant, as AP3B1 itself is not a therapeutic drug target, but genetic disruption leads to multi-system disease including bleeding, immunodeficiency, and risk of fatal complications in HPS2
05

Biomarkers

AP3B1 gene mutation analysis for Hermansky-Pudlak syndrome type 2 (HPS2) diagnosisProtein quantification/qualitative analysis (as part of lysosomal/vesicular diagnostics)

Beyond the preview

Go deeper on Adaptor protein complex AP-3 subunit beta-1 (AP3B1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adaptor protein complex AP-3 subunit beta-1 (AP3B1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call